Nuveen Asset Management, LLC Chinook Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $1.31 Million - $2.71 Million	-70,344 Reduced 9.43%	675,828 $26 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $3.67 Million - $4.57 Million	-170,593 Reduced 18.61%	746,172 $17.3 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $828,904 - $1.22 Million	-44,493 Reduced 4.63%	916,765 $18.4 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $5.88 Million - $7.85 Million	336,054 Added 53.75%	961,258 $18.9 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $5.17 Million - $7.72 Million	410,711 Added 191.48%	625,204 $10.9 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $723,087 - $1 Million	60,157 Added 38.98%	214,493 $3.51 Million
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $254,625 - $400,873	-23,819 Reduced 13.37%	154,336 $2.52 Million
Q3 2021 Nov 12, 2021	SELL	$11.5 - $14.86 $71,656 - $92,592	-6,231 Reduced 3.38%	178,155 $2.27 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $1.52 Million - $2.12 Million	111,751 Added 153.85%	184,386 $1.5 Million
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $34,787 - $46,915	-2,455 Reduced 3.27%	72,635 $1.03 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $893,571 - $1.57 Million	75,090 New	75,090 $1.19 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.